Novelos gets notice of allowance for fifth U.S. patent

By Elaine Rigoli

Tampa, Fla., Sept. 11 - Novelos Therapeutics, Inc. has received a notice of allowance from the U.S. Patent and Trademark Office for its patent application extending the composition and method of use claims relating to NOV-002, its lead compound in phase 3 development for non-small cell lung cancer under a Special Protocol Assessment and fast-track designation.

The Newton, Mass.-based biotechnology company said that, in addition to the newly allowed U.S. patent, its intellectual property includes four earlier issued U.S. patents, two European and two Japanese issued patents, as well as 30 patent applications filed worldwide.

The company said this recent addition will expand its pipeline to include additional compounds based on this structural motif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.